BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Special Report

iNtRON Bio Unveils World-First Dual-Action Engineered Phage Targeting Colorectal Cancer-Causing Bacteria

Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeut...

August 06, 2025 | News

Precision Therapies Set to Unlock USD 1.6 Trillion in Economic Impact Across Asia-Pacific

As Asia-Pacific bears nearly half of the global cancer burden, precision medicine is emerging not only as a clinical breakthrough but also as a powerful ec...

August 04, 2025 | Interview

Eflornithine Added to Australia’s PBS for Children with High-Risk Neuroblastoma

Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory C...

August 04, 2025 | News

Johor’s Healthcare Transformation: Billions Poured into Malaysia’s Life Sciences Engine (2022–2025)

Johor’s Healthcare & Life Sciences Investment Boom (2022–2025) Over the past three years, the southern Malaysian state of Johor has emerge...

July 30, 2025 | Report

Suzhou’s Kintor Pharma Reports Positive Phase II Results for KX-826 in AGA Trial, Clears Path for Phase III

Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and po...

July 28, 2025 | News

3 Trillion-Dollar Sectors, 2 Nations, 1 Game-Changing Deal: UK-India FTA and the Future of Life Sciences

UK-India FTA and Life Sciences: A Strategic Partnership for Growth The UK-India trade relationship has been evolving rapidly, culminating in a landmark Fr...

July 28, 2025 | Analysis

How Innovation Gaps in Biopharma Raise New Safety Concerns

The biopharmaceutical industry stands at the forefront of medical innovation and delivers remarkable advances in disease treatment and prevention. Breakthr...

July 24, 2025 | News

Asia Pacific on the Brink of a Healthcare Transformation with the Arrival of the Precision Era

The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, a...

July 22, 2025 | News

How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress

While innovation drives progress, the absence of consistent ethical safeguards in psychiatry can distort research outcomes and undermine clinical trials. S...

July 21, 2025 | News

BioPharma in APAC: Mid-Year Report 2025 – Tracking Progress, Trends & Possibilities Ahead

As we cross the midpoint of 2025, BioPharma APAC presents this Mid-Year Report—an incisive look at emerging biopharmaceutical dynamics, key i...

July 21, 2025 | Analysis

Using NLP-Driven Decision Support in Emergency Health Assistance

According to the US Department of Transportation, over 40,000 lives were lost in roadway deaths in 2023. The CDC reports that the country saw appro...

July 14, 2025 | News

FDA Publishes First-Ever Public Database of Complete Response Letters (2020–2024) – Now Available for Download

Download Approved CRLs – 2020 to 2024 (external link) U.S. Food and Drug Administration (FDA) has, for the first time, made pub...

July 14, 2025 | Regulatory

No More Whisper Networks: FDA Puts Its Rejection Reasons in Writing — Publicly

FDA Embraces Radical Transparency by Publishing Complete Response Letters For Immediate Release: July 10, 2025 &nb...

July 11, 2025 | News

FDA’s Most Recent 100 Warning Letters of 2025 Signal Rising Compliance Risks Across Pharma, Biologics, Devices, Food, and Online Markets

As of July 2025, the U.S. Food and Drug Administration (FDA) has issued over 3,400 warning letters, with the most recent 100 painting a vivid pictu...

July 11, 2025 | Analysis | By BioPharma APAC Desk

Stay Connected